• Something wrong with this record ?

Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial

AM. Lincoff, M. Roe, P. Aylward, J. Galla, A. Rynkiewicz, V. Guetta, M. Zelizko, N. Kleiman, H. White, E. McErlean, D. Erlinge, M. Laine, JM. Dos Santos Ferreira, S. Goodman, S. Mehta, D. Atar, H. Suryapranata, SE. Jensen, T. Forster, A....

. 2014 ; 35 (37) : 2516-23.

Language English Country England, Great Britain

Document type Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc15023441

AIMS: Delcasertib is a selective inhibitor of delta-protein kinase C (delta-PKC), which reduced infarct size during ischaemia/reperfusion in animal models and diminished myocardial necrosis and improved reperfusion in a pilot study during primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI). METHODS AND RESULTS: A multicentre, double-blind trial was performed in patients presenting within 6 h and undergoing primary PCI for anterior (the primary analysis cohort, n = 1010 patients) or inferior (an exploratory cohort, capped at 166 patients) STEMI. Patients with anterior STEMI were randomized to placebo or one of three doses of delcasertib (50, 150, or 450 mg/h) by intravenous infusion initiated before PCI and continued for ∼2.5 h. There were no differences between treatment groups in the primary efficacy endpoint of infarct size measured by creatine kinase MB fraction area under the curve (AUC) (median 5156, 5043, 4419, and 5253 ng h/mL in the placebo, delcasertib 50, 150, and 450 mg/mL groups, respectively) in the anterior STEMI cohort. No treatment-related differences were seen in secondary endpoints of infarct size, electrocardiographic ST-segment recovery AUC or time to stable ST recovery, or left ventricular ejection fraction at 3 months. No differences in rates of adjudicated clinical endpoints (death, heart failure, or serious ventricular arrhythmias) were observed. CONCLUSIONS: Selective inhibition of delta-PKC with intravenous infusion of delcasertib during PCI for acute STEMI in a population of patients treated according to contemporary standard of care did not reduce biomarkers of myocardial injury.

Canadian Heart Research Centre and St Michael's HospitalUniversity of Toronto Toronto Ontario Canada

Cleveland Clinic Coordinating Center for Clinical Research Cleveland OH USA

Coronary Care Unit Hospital Clinico San Carlos Madrid Spain

Department of Cardiology and Cardiosurgery University of Warmia and Mazury Olsztyn Poland

Department of Cardiology Angiology Intensive Care Medicine University of Schleswig Holstein Lübeck Germany

Department of Cardiology Århus University Hospital Aalborg Denmark

Department of Cardiology B Oslo University Hospital Norway and Institute of Clinical Sciences University of Oslo Oslo Norway

Department of Cardiology Hamilton General Hospital Hamilton Ontario Canada

Department of Cardiology Hospital Santa Cruz Carnaxide Portugal

Department of Cardiology Institute for Clinical and Experimental Medicine Prague Czech Republic

Department of Cardiology Lund University Lund Sweden

Department of Cardiology Radboud University Nijmegen Medical Center The Netherlands

Division of Cardiology Helsinki University Central Hospital Helsinki Finland

Duke Clinical Research Institute Durham NC USA

Flinders University and Medical Centre Adelaide Australia

Green Lane Cardiovascular Service Auckland City Hospital Auckland New Zealand

Heart Institute Sheba Medical Center Tel Hashomer Israel

Interventional Department Universitair Ziekenhuis Brussel Belgium

KAI Phamaceuticals and Department of Medicine University of California San Francisco San Francisco CA USA

Medical Faculty University of Szeged and Albert Szent Gyorgyi Medical and Pharmaceutical Center Szeged Hungary

Methodist DeBakey Heart and Vascular Center Houston TX USA

Unita Operativa di Emodinamica e Cardiologia Invasiva Istitutio Clinico Humanitas Milano Italy

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15023441
003      
CZ-PrNML
005      
20150729121909.0
007      
ta
008      
150709s2014 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1093/eurheartj/ehu177 $2 doi
035    __
$a (PubMed)24796339
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Lincoff, A Michael $u Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland, OH, USA lincofa@ccf.org.
245    10
$a Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the PROTECTION AMI Randomized Controlled Trial / $c AM. Lincoff, M. Roe, P. Aylward, J. Galla, A. Rynkiewicz, V. Guetta, M. Zelizko, N. Kleiman, H. White, E. McErlean, D. Erlinge, M. Laine, JM. Dos Santos Ferreira, S. Goodman, S. Mehta, D. Atar, H. Suryapranata, SE. Jensen, T. Forster, A. Fernandez-Ortiz, D. Schoors, P. Radke, G. Belli, D. Brennan, G. Bell, M. Krucoff, . ,
520    9_
$a AIMS: Delcasertib is a selective inhibitor of delta-protein kinase C (delta-PKC), which reduced infarct size during ischaemia/reperfusion in animal models and diminished myocardial necrosis and improved reperfusion in a pilot study during primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI). METHODS AND RESULTS: A multicentre, double-blind trial was performed in patients presenting within 6 h and undergoing primary PCI for anterior (the primary analysis cohort, n = 1010 patients) or inferior (an exploratory cohort, capped at 166 patients) STEMI. Patients with anterior STEMI were randomized to placebo or one of three doses of delcasertib (50, 150, or 450 mg/h) by intravenous infusion initiated before PCI and continued for ∼2.5 h. There were no differences between treatment groups in the primary efficacy endpoint of infarct size measured by creatine kinase MB fraction area under the curve (AUC) (median 5156, 5043, 4419, and 5253 ng h/mL in the placebo, delcasertib 50, 150, and 450 mg/mL groups, respectively) in the anterior STEMI cohort. No treatment-related differences were seen in secondary endpoints of infarct size, electrocardiographic ST-segment recovery AUC or time to stable ST recovery, or left ventricular ejection fraction at 3 months. No differences in rates of adjudicated clinical endpoints (death, heart failure, or serious ventricular arrhythmias) were observed. CONCLUSIONS: Selective inhibition of delta-PKC with intravenous infusion of delcasertib during PCI for acute STEMI in a population of patients treated according to contemporary standard of care did not reduce biomarkers of myocardial injury.
650    _2
$a senioři $7 D000368
650    _2
$a plocha pod křivkou $7 D019540
650    _2
$a biologické markery $x metabolismus $7 D015415
650    _2
$a adjuvantní chemoterapie $7 D017024
650    _2
$a kreatinkinasa, forma MB $x metabolismus $7 D052279
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a intravenózní infuze $7 D007262
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a infarkt myokardu $x terapie $7 D009203
650    _2
$a peptidy $x aplikace a dávkování $7 D010455
650    _2
$a koronární angioplastika $x metody $7 D062645
650    _2
$a pilotní projekty $7 D010865
650    _2
$a inhibitory proteinkinas $x aplikace a dávkování $7 D047428
650    _2
$a výsledek terapie $7 D016896
650    _2
$a troponin I $x metabolismus $7 D019210
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Roe, Matthew $u Duke Clinical Research Institute, Durham, NC, USA.
700    1_
$a Aylward, Philip $u Flinders University and Medical Centre, Adelaide, Australia. $7 gn_A_00010588
700    1_
$a Galla, John $u Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland, OH, USA.
700    1_
$a Rynkiewicz, Andrzej $u Department of Cardiology and Cardiosurgery, University of Warmia and Mazury, Olsztyn, Poland.
700    1_
$a Guetta, Victor $u Heart Institute, Sheba Medical Center, Tel Hashomer, Israel.
700    1_
$a Zelizko, Michael $u Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
700    1_
$a Kleiman, Neal $u Methodist DeBakey Heart & Vascular Center, Houston, TX, USA.
700    1_
$a White, Harvey $u Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand.
700    1_
$a McErlean, Ellen $u Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland, OH, USA.
700    1_
$a Erlinge, David $u Department of Cardiology, Lund University, Lund, Sweden.
700    1_
$a Laine, Mika $u Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland.
700    1_
$a Dos Santos Ferreira, Jorge Manuel $u Department of Cardiology, Hospital Santa Cruz, Carnaxide, Portugal.
700    1_
$a Goodman, Shaun $u Canadian Heart Research Centre and St. Michael's HospitalUniversity of Toronto, Toronto, Ontario, Canada.
700    1_
$a Mehta, Shamir $u Department of Cardiology, Hamilton General Hospital Hamilton, Ontario, Canada.
700    1_
$a Atar, Dan $u Department of Cardiology B, Oslo University Hospital, Norway, and Institute of Clinical Sciences, University of Oslo, Oslo, Norway. $7 gn_A_00009712
700    1_
$a Suryapranata, Harry $u Department of Cardiology, Radboud University Nijmegen Medical Center, The Netherlands.
700    1_
$a Jensen, Svend Eggert $u Department of Cardiology, Århus University Hospital, Aalborg, Denmark.
700    1_
$a Forster, Tamas $u Medical Faculty, University of Szeged and Albert Szent-Gyorgyi Medical and Pharmaceutical Center, Szeged, Hungary.
700    1_
$a Fernandez-Ortiz, Antonio $u Coronary Care Unit, Hospital Clinico San Carlos, Madrid, Spain.
700    1_
$a Schoors, Danny $u Interventional Department, Universitair Ziekenhuis Brussel, Belgium.
700    1_
$a Radke, Peter $u Department of Cardiology, Angiology, Intensive Care Medicine, University of Schleswig Holstein, Lübeck, Germany.
700    1_
$a Belli, Guido $u Unita Operativa di Emodinamica e Cardiologia Invasiva Istitutio Clinico Humanitas, Milano, Italy.
700    1_
$a Brennan, Danielle $u Cleveland Clinic Coordinating Center for Clinical Research (C5Research), Cleveland, OH, USA.
700    1_
$a Bell, Gregory $u KAI Phamaceuticals and Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
700    1_
$a Krucoff, Mitchell $u Duke Clinical Research Institute, Durham, NC, USA.
700    1_
$a ,
773    0_
$w MED00009622 $t European heart journal $x 1522-9645 $g Roč. 35, č. 37 (2014), s. 2516-23
856    41
$u https://pubmed.ncbi.nlm.nih.gov/24796339 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150709 $b ABA008
991    __
$a 20150729121955 $b ABA008
999    __
$a ok $b bmc $g 1083778 $s 906434
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 35 $c 37 $d 2516-23 $i 1522-9645 $m European heart journal $n Eur Heart J $x MED00009622
LZP    __
$a Pubmed-20150709

Find record

Citation metrics

Archiving options